| Title |
Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
|
|---|---|
| Published in |
Neurotherapeutics, January 2015
|
| DOI | 10.1007/s13311-014-0304-z |
| Pubmed ID | |
| Authors |
Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, María L. Bellido, Eduardo Muñoz, Onintza Sagredo |
| Abstract |
Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in experimental models of Huntington's disease (HD) through cannabinoid receptor-dependent and/or independent mechanisms. Herein, we studied the effects of cannabigerol (CBG), a nonpsychotropic phytocannabinoid, in 2 different in vivo models of HD. CBG was extremely active as neuroprotectant in mice intoxicated with 3-nitropropionate (3NP), improving motor deficits and preserving striatal neurons against 3NP toxicity. In addition, CBG attenuated the reactive microgliosis and the upregulation of proinflammatory markers induced by 3NP, and improved the levels of antioxidant defenses that were also significantly reduced by 3NP. We also investigated the neuroprotective properties of CBG in R6/2 mice. Treatment with this phytocannabinoid produced a much lower, but significant, recovery in the deteriorated rotarod performance typical of R6/2 mice. Using HD array analysis, we were able to identify a series of genes linked to this disease (e.g., symplekin, Sin3a, Rcor1, histone deacetylase 2, huntingtin-associated protein 1, δ subunit of the gamma-aminobutyric acid-A receptor (GABA-A), and hippocalcin), whose expression was altered in R6/2 mice but partially normalized by CBG treatment. We also observed a modest improvement in the gene expression for brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and peroxisome proliferator-activated receptor-γ (PPARγ), which is altered in these mice, as well as a small, but significant, reduction in the aggregation of mutant huntingtin in the striatal parenchyma in CBG-treated animals. In conclusion, our results open new research avenues for the use of CBG, alone or in combination with other phytocannabinoids or therapies, for the treatment of neurodegenerative diseases such as HD. |
X Demographics
The data shown below were collected from the profiles of 47 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 15% |
| France | 7 | 15% |
| Spain | 3 | 6% |
| Portugal | 2 | 4% |
| Cameroon | 1 | 2% |
| South Africa | 1 | 2% |
| Djibouti | 1 | 2% |
| Canada | 1 | 2% |
| Colombia | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 22 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 45 | 96% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 225 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 2 | <1% |
| Spain | 2 | <1% |
| United Kingdom | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 218 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 50 | 22% |
| Student > Master | 31 | 14% |
| Student > Ph. D. Student | 26 | 12% |
| Student > Bachelor | 20 | 9% |
| Other | 19 | 8% |
| Other | 29 | 13% |
| Unknown | 50 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 31 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 12% |
| Biochemistry, Genetics and Molecular Biology | 25 | 11% |
| Neuroscience | 20 | 9% |
| Medicine and Dentistry | 17 | 8% |
| Other | 45 | 20% |
| Unknown | 60 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 147. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#285,120
of 25,738,558 outputs
Outputs from Neurotherapeutics
#30
of 1,318 outputs
Outputs of similar age
#3,202
of 361,531 outputs
Outputs of similar age from Neurotherapeutics
#1
of 20 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,318 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,531 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.